High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types.
暂无分享,去创建一个
Masanori Nakagawa | Yasuyoshi Watanabe | Rachel Mulligan | Christopher C Rowe | Toshiki Mizuno | Colin L Masters | Masaki Kondo | Victor L Villemagne | Hiroshi Mori | C. Rowe | C. Masters | Yasuyoshi Watanabe | W. Brooks | R. Mulligan | G. O'Keefe | Gareth Jones | V. Villemagne | M. Nakagawa | H. Mori | T. Mizuno | Yasuhiro Wada | Takami Miki | Gareth Jones | Yasuhiro Wada | Hiroyuki Shimada | Suzuka Ataka | William S Brooks | T. Miki | Graeme J O'Keefe | S. Ataka | H. Shimada | M. Kondo
[1] W. K. Cullen,et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.
[2] J. Morris,et al. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage alzheimer’s disease , 2001, Journal of Molecular Neuroscience.
[3] Gina N. LaRossa,et al. [11C]PIB in a nondemented population , 2006, Neurology.
[4] R. Frackowiak,et al. Clinical and Neuroimaging Features of Familial Alzheimer's Disease a , 1996, Annals of the New York Academy of Sciences.
[5] S. Younkin,et al. The APP and PS1/2 Mutations Linked to Early Onset Familial Alzheimer’s Disease Increase the Extracellular Concentration of Aβ1–42(43) , 1998 .
[6] Colin L Masters,et al. Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics , 2006, Journal of neurochemistry.
[7] Paul Edison,et al. Amyloid load and cerebral atrophy in Alzheimer's disease: An 11C‐PIB positron emission tomography study , 2006, Annals of neurology.
[8] Yasuyoshi Watanabe,et al. A new amyloid β variant favoring oligomerization in Alzheimer's‐type dementia , 2008, Annals of neurology.
[9] Karl J. Friston,et al. Comparing Functional (PET) Images: The Assessment of Significant Change , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[10] S. DeKosky,et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease , 2008, Brain : a journal of neurology.
[11] C. Rowe,et al. Aβ deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease , 2008, Neuropsychologia.
[12] P. Schofield,et al. Variable phenotype of Alzheimer’s disease with spastic paraparesis , 2007, Annals of neurology.
[13] D. Pollen,et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease , 1995, Nature.
[14] Majaz Moonis,et al. Amyloid Deposition Begins in the Striatum of Presenilin-1 Mutation Carriers from Two Unrelated Pedigrees , 2007, The Journal of Neuroscience.
[15] S. Leurgans,et al. Cortical biochemistry in MCI and Alzheimer disease , 2007, Neurology.
[16] Molecular genetics of Alzheimer’s disease , 2000, Biological Psychiatry.
[17] Jeffrey A. James,et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. , 2008, Archives of neurology.
[18] J. Morris,et al. Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease , 1999, Annals of neurology.
[19] D. Pollen,et al. Familial and sporadic Alzheimer's disease , 1996, Neurology.
[20] Tetsuya Suhara,et al. Longitudinal, Quantitative Assessment of Amyloid, Neuroinflammation, and Anti-Amyloid Treatment in a Living Mouse Model of Alzheimer's Disease Enabled by Positron Emission Tomography , 2007, The Journal of Neuroscience.
[21] B. Ghetti,et al. A novel mutation (G217D) in the Presenilin 1 gene (PSEN1) in a Japanese family: presenile dementia and parkinsonism are associated with cotton wool plaques in the cortex and striatum , 2002, Acta Neuropathologica.
[22] W. Klunk,et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.
[23] M. D. de Leon,et al. Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[24] G. Alexander,et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. , 2001, JAMA.
[25] H. Levine,et al. Diversity of Abeta deposits in the aged brain: a window on molecular heterogeneity? , 2008, Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie.
[26] C. Rowe,et al. Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism , 2008, The Lancet Neurology.
[27] T. Bird. Genetic aspects of Alzheimer disease , 2008, Genetics in Medicine.
[28] Nick C Fox,et al. Amyloid, hypometabolism, and cognition in Alzheimer disease , 2007, Neurology.
[29] M. Doran,et al. Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin–1 gene , 2006, Journal of Neurology.
[30] C. Masters,et al. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease , 1999, Annals of neurology.
[31] K. Davis,et al. Dissociation of neuropathology from severity of dementia in late-onset Alzheimer disease , 2006, Neurology.
[32] A. Paetau,et al. PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease. , 2008, Brain : a journal of neurology.
[33] J. Morrison,et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease , 2003, Neurology.
[34] K. Davis,et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. , 2000, JAMA.
[35] H. Engler,et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. , 2006, Brain : a journal of neurology.
[36] T. Tabira,et al. Alzheimer's disease with spastic paresis and cotton wool type plaques , 2002, Journal of neuroscience research.
[37] A. Gee,et al. Evidence for the Presence of Three Distinct Binding Sites for the Thioflavin T Class of Alzheimer's Disease PET Imaging Agents on β-Amyloid Peptide Fibrils* , 2005, Journal of Biological Chemistry.
[38] Christopher C Rowe,et al. Visual Assessment Versus Quantitative Assessment of 11C-PIB PET and 18F-FDG PET for Detection of Alzheimer's Disease , 2007, Journal of Nuclear Medicine.
[39] J. Schneider,et al. Neuropathology of older persons without cognitive impairment from two community-based studies , 2006, Neurology.
[40] J. Busciglio,et al. Different Conformations of Amyloid β Induce Neurotoxicity by Distinct Mechanisms in Human Cortical Neurons , 2006, The Journal of Neuroscience.
[41] C. Rowe,et al. Imaging β-amyloid burden in aging and dementia , 2007, Neurology.
[42] Lars Bertram,et al. New Frontiers in Alzheimer's Disease Genetics , 2001, Neuron.
[43] Gina N. LaRossa,et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.
[44] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease , 1984, Neurology.
[45] Paul Maruff,et al. β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease , 2007 .
[46] R. Neve,et al. Alzheimer’s disease: a dysfunction of the amyloid precursor protein 1 1 Published on the World Wide Web on 11 September 2000. , 2000, Brain Research.
[47] Richard S. J. Frackowiak,et al. Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease , 1995, Neuroscience Letters.
[48] M. Menéndez. Pathological and clinical heterogeneity of presenilin 1 gene mutations. , 2004, Journal of Alzheimer's disease : JAD.